Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells 7,000 Shares of Stock

Key Points

• Director Johannes Gerardus Chri Schikan sold 7,000 shares on April 22 at an average price of $30.05 for about $210,350, reducing his stake to 388,167 shares (a 1.77% ownership decline); he also sold 100 shares on April 23.
• PHVS traded near $28.54 with a market cap of $1.87 billion, a negative P/E, a 52-week range of $14.59–$30.24, and analysts forecast about -3.19 EPS for the year.
• Analysts give PHVS a consensus rating of "Moderate Buy" with an average price target of $42.73 (11 Buys, 2 Holds, 1 Sell), and several large institutions hold or have recently increased positions.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $30.05, for a total value of $210,350.00. Following the transaction, the director directly owned 388,167 shares of the company's stock, valued at approximately $11,664,418.35. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.

Pharvaris Stock Performance

PHVS stock traded up $1.25 during midday trading on Friday, hitting $28.54. 129,619 shares of the stock were exchanged, compared to its average volume of 172,220. The stock's 50-day moving average price is $27.39 and its 200-day moving average price is $25.80. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -8.47 and a beta of -2.58. Pharvaris N.V. has a fifty-two week low of $14.59 and a fifty-two week high of $30.24.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Research analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. General Atlantic L.P. grew its position in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock valued at $200,380,000 after purchasing an additional 500,000 shares during the period. Foresite Capital Management IV LLC grew its position in Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company's stock valued at $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC grew its position in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company's stock valued at $115,751,000 after acquiring an additional 350,000 shares during the period. Deerfield Management Company L.P. grew its position in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company's stock valued at $60,939,000 after acquiring an additional 425,000 shares during the period. Finally, Commodore Capital LP grew its position in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company's stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PHVS. Wolfe Research began coverage on Pharvaris in a report on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a report on Tuesday. Citigroup reissued a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a report on Monday, April 6th. Finally, Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a report on Tuesday, April 7th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.